Anthony Nolan has announced that 29 jobs are at risk as it looks to cut costs due to Covid-19 income losses.
The measures have been taken as the blood cancer charity looks to continue delivering support services to patients and their families, as well as invest in research.
Another key service it is prioritising is matching stem cell donors to those in need of a transplant.
The COVID-19 pandemic has posed many challenges, and we need to do all we can to be there for patients now and into the future.— Anthony Nolan (@AnthonyNolan) August 17, 2020
We’re really sad to announce that today we shared proposals to reduce the size of the Anthony Nolan team.
Our full statement👇 https://t.co/f0ZnzbugLF
Proposed changes include restructuring the fundraising department due to the loss of income, particularly from events.
The charity is looking to complete its cost cutting plans by the end of October.
“The demand for our lifesaving work hasn’t stopped and the support for our patients is ever more important, but the world in which we are operating is changing at a pace and scale that no one could have predicted,” said the charity’s chief executive Henry Braund.
“Anthony Nolan is made up of passionate people working to save the lives of people with blood cancer and we take that responsibility incredibly seriously. We work with brilliant and talented colleagues which has made the decision to drive structural change all the more difficult.
“We have to evolve as an organisation to ensure that we can be here for patients now and into the future. We need to ensure our hard earned funds are used to support this work and the critical research that will improve the chances for patients.
“The proposals set out a clear plan for our new business model and we are working to support any staff who may be affected as a result of the proposals and these difficult times”.
So far this year 5,000 charity workers have either lost their job or their roles have been earmarked for redundancy. The figures were released this month by New Philanthropy Capital.